PRIME
Research type
Research Study
Full title
PRIME-PPF: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis An International Prospective Cohort Study of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
IRAS ID
358618
Contact name
Philip Molyneaux
Contact email
Sponsor organisation
UMass Chan Medical School
Clinicaltrials.gov Identifier
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Interstitial lung diseases (ILD) are a group of disorders characterized by progressive scarring (fibrosis) of the lung tissue leading to difficulty breathing. Progressive pulmonary fibrosis (PPF) is when the fibrosis worsens over time.
PPF is a serious condition, but there is still a lot we don’t know about it. Most research has focused on IPF, which leads to ongoing lung damage and has a survival rate worse than many cancers. PPF (non-IPF ILD) is just as serious but has not been studied as much. This means doctors don’t have enough information to predict how the disease will progress or how to best treat it.
The purpose of this research study is to collect information and samples from you to get a better understanding of natural history of how PPF progresses over time. Our goal is to use the findings from this study to help us identify which patients with ILD are more likely to develop PPF, so that we can better treat people with PPF in the future.
REC name
Wales REC 1
REC reference
25/WA/0251
Date of REC Opinion
24 Sep 2025
REC opinion
Further Information Favourable Opinion